GlassScriptPhysician profile
Kruti P Patel
NPI 1760898373
$10,985.44
in general payments reported to CMS, 2019-2025
29 companies · $346 in 2025
The $346 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,314 · 2020: $4,242 · 2021: $662 · 2022: $707 · 2023: $574 · 2024: $1,140 · 2025: $346.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393 · Travel and Lodging: $640 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.98 |
| Travel and Lodging | $640.28 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $4,187.24 | 2019-2020 | |
| Medtronic Vascular, INC. | $1,852.00 | 2020 | |
| Abbott Laboratories | $1,252.82 | 2019-2025 | Mitraclip, Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $830.63 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $663.95 | 2019-2024 | Farxiga |
| Pfizer INC. | $453.52 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $312.59 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $160.84 | 2021-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $153.89 | 2023-2024 | Sapien 3 Ultra Resilia, Pascal |
| Merck Sharp & Dohme LLC | $153.44 | 2019-2024 | Verquvo |
| Lantheus Medical Imaging, INC. | $119.59 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $106.04 | 2019-2023 | Lifevest |
| Btg International INC. | $100.80 | 2019 | |
| Braemar Manufacturing, LLC | $72.77 | 2019 | |
| United Therapeutics Corporation | $72.57 | 2020-2025 | Tyvaso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Irhythm Technologies, INC. | $60.93 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $56.86 | 2019-2024 | Cresemba |
| Akcea Therapeutics, INC. | $43.85 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.46 | 2021-2024 | Jardiance |
| Novo Nordisk INC | $36.65 | 2020-2024 | |
| Baxter Healthcare | $36.48 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Bridgebio Pharma, INC. | $35.47 | 2025 | Attruby |
| Amgen INC. | $32.91 | 2019-2021 | |
| Abiomed | $30.55 | 2025 | |
| Innovation Technologies INC | $29.52 | 2025 | Irrisept |
| Silk Road Medical, INC. | $26.94 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Regeneron Healthcare Solutions, INC. | $24.59 | 2025 | Evkeeza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.45 | 2021 | |
| Boston Scientific Corporation | $17.09 | 2023 | Watchman Access System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kruti Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.